About
Ophthalmology biotech developing Restoret (EYE103), a tri-specific antibody for DME. Acquired by Merck (announced 2024) for $1.3bn upfront + up to $1.7bn milestones.
HQ: London, UK
Funding
Acquired by Merck (2024)
—Company profile
Restoret (EYE103) — a Wnt-pathway candidate for diabetic macular edema; acquired by Merck for up to $3bn.
Ophthalmology biotech developing Restoret (EYE103), a tri-specific antibody for DME. Acquired by Merck (announced 2024) for $1.3bn upfront + up to $1.7bn milestones.
HQ: London, UK